CN114585416B - 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体 - Google Patents
用于调节免疫应答和治疗疾病的btla结合(cd272)抗体 Download PDFInfo
- Publication number
- CN114585416B CN114585416B CN202080040939.4A CN202080040939A CN114585416B CN 114585416 B CN114585416 B CN 114585416B CN 202080040939 A CN202080040939 A CN 202080040939A CN 114585416 B CN114585416 B CN 114585416B
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- btla
- amino acid
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411950244.6A CN119735682A (zh) | 2019-04-01 | 2020-03-31 | 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962827744P | 2019-04-01 | 2019-04-01 | |
| US62/827,744 | 2019-04-01 | ||
| PCT/US2020/025936 WO2020205849A1 (en) | 2019-04-01 | 2020-03-31 | Btla-binding (cd272) antibodies for modulating immune response and treating disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411950244.6A Division CN119735682A (zh) | 2019-04-01 | 2020-03-31 | 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114585416A CN114585416A (zh) | 2022-06-03 |
| CN114585416B true CN114585416B (zh) | 2025-01-17 |
Family
ID=70296156
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080040939.4A Active CN114585416B (zh) | 2019-04-01 | 2020-03-31 | 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体 |
| CN202411950244.6A Pending CN119735682A (zh) | 2019-04-01 | 2020-03-31 | 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411950244.6A Pending CN119735682A (zh) | 2019-04-01 | 2020-03-31 | 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11384146B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3946622A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7596298B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220047536A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114585416B (cg-RX-API-DMAC7.html) |
| CA (2) | CA3302760A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286838A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020205849A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023004633A (es) * | 2020-10-23 | 2023-05-12 | Anaptysbio Inc | Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. |
| MX2024007054A (es) * | 2021-12-10 | 2024-09-04 | Merck Sharp & Dohme Llc | Aglutinantes de mesotelina humana. |
| EP4469558A4 (en) * | 2022-01-29 | 2026-02-25 | Hifibio Inc | Anti-BTLA antibodies and their uses in cancer treatment |
| AU2023212896A1 (en) * | 2022-01-29 | 2024-08-22 | Hifibio, Inc. | Antibody against btla and uses thereof |
| US20230322929A1 (en) * | 2022-04-12 | 2023-10-12 | Shanghai Junshi Biosciences Co., Ltd. | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy |
| EP4558226A1 (en) * | 2022-07-19 | 2025-05-28 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2025250861A1 (en) * | 2024-05-31 | 2025-12-04 | Icahn School Of Medicine At Mount Sinai | Broadly neutralizing anti-hcmv antibodies and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101888878A (zh) * | 2007-09-26 | 2010-11-17 | 健泰科生物技术公司 | 新型抗体 |
| CN108925136A (zh) * | 2015-12-02 | 2018-11-30 | 斯特赛恩斯公司 | 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US7153950B2 (en) | 2002-10-25 | 2006-12-26 | Genentech, Inc. | Nucleic acids encoding an immune related polypeptide |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| CA2769473A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| EP3288587A4 (en) | 2015-04-29 | 2018-09-12 | Sanford-Burnham Medical Research Institute | Modulation of immune response using btla agonist antibodies |
| CA3013333A1 (en) * | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| PE20190115A1 (es) * | 2016-04-15 | 2019-01-16 | Immunext Inc | Anticuerpos vista antihumanos y su uso |
-
2020
- 2020-03-31 CN CN202080040939.4A patent/CN114585416B/zh active Active
- 2020-03-31 US US16/836,006 patent/US11384146B2/en active Active
- 2020-03-31 CA CA3302760A patent/CA3302760A1/en active Pending
- 2020-03-31 JP JP2021560478A patent/JP7596298B2/ja active Active
- 2020-03-31 EP EP20720302.7A patent/EP3946622A1/en active Pending
- 2020-03-31 CA CA3135836A patent/CA3135836A1/en active Pending
- 2020-03-31 CN CN202411950244.6A patent/CN119735682A/zh active Pending
- 2020-03-31 WO PCT/US2020/025936 patent/WO2020205849A1/en not_active Ceased
- 2020-03-31 KR KR1020217035131A patent/KR20220047536A/ko active Pending
-
2021
- 2021-09-30 IL IL286838A patent/IL286838A/en unknown
-
2022
- 2022-07-10 US US17/811,586 patent/US20230340123A1/en active Pending
-
2024
- 2024-11-27 JP JP2024206358A patent/JP7875929B2/ja active Active
-
2026
- 2026-03-16 JP JP2026042113A patent/JP2026102772A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101888878A (zh) * | 2007-09-26 | 2010-11-17 | 健泰科生物技术公司 | 新型抗体 |
| CN108925136A (zh) * | 2015-12-02 | 2018-11-30 | 斯特赛恩斯公司 | 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230340123A1 (en) | 2023-10-26 |
| JP2022528005A (ja) | 2022-06-07 |
| CA3135836A1 (en) | 2020-10-08 |
| JP2026102772A (ja) | 2026-06-23 |
| JP7596298B2 (ja) | 2024-12-09 |
| WO2020205849A1 (en) | 2020-10-08 |
| EP3946622A1 (en) | 2022-02-09 |
| US20200325230A1 (en) | 2020-10-15 |
| IL286838A (en) | 2021-10-31 |
| CN119735682A (zh) | 2025-04-01 |
| CN114585416A (zh) | 2022-06-03 |
| KR20220047536A (ko) | 2022-04-18 |
| JP2025041629A (ja) | 2025-03-26 |
| JP7875929B2 (ja) | 2026-06-18 |
| US11384146B2 (en) | 2022-07-12 |
| CA3302760A1 (en) | 2026-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7596298B2 (ja) | 免疫応答を調節するためおよび疾患を処置するためのbtla結合(cd272)抗体 | |
| US12404327B2 (en) | LILRB3-binding molecules and uses therefor | |
| KR20210138674A (ko) | Tsg-6 항체 및 그 용도 | |
| US20240150462A1 (en) | Lilrb1 and lilrb2-binding molecules and uses therefor | |
| TWI857009B (zh) | Fcmr結合分子及其用途 | |
| EA046937B1 (ru) | Lilrb3-связывающие молекулы и варианты их применения | |
| JP2022525261A (ja) | ビスタ結合抗体およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: California, USA Patentee after: Kuria Biotechnology Co.,Ltd. Country or region after: U.S.A. Patentee after: Trianni S.A. Address before: California, USA Patentee before: Lake Pharmaceutical Co.,Ltd. Country or region before: U.S.A. Patentee before: Trianni S.A. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20250123 Address after: New York, United States Patentee after: Kuria Intellectual Property Holdings LLC Country or region after: U.S.A. Patentee after: Trianni S.A. Address before: California, USA Patentee before: Kuria Biotechnology Co.,Ltd. Country or region before: U.S.A. Patentee before: Trianni S.A. |
|
| TR01 | Transfer of patent right |